ArticleBlood advances2021
Relationship of donor age and relationship to outcomes of haploidentical transplantation with posttransplant cyclophosphamide.
Article in Blood advances, 2021. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 72 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
72 citing papers in PubMed, 99 citations in OpenAlex.
- Trial
- Nonmyeloablative, HLA-Mismatched Unrelated Peripheral Blood Transplantation with High-Dose Post-Transplantation Cyclophosphamide.Transplantation and cellular therapy · 2021Trial
- The Pitfalls of Categorizing Donor Age: Arbitrary Cutoffs Fail to Predict Survival in Haploidentical HCT.American journal of hematology · 2026Article
- Donor selection for allogeneic hematopoietic cell transplantation in the posttransplant cyclophosphamide era.International journal of hematology · 2026Review
- Optimal donor selection for transplant to reduce GVHD risk and augment graft-versus-malignancy efficacy.Current opinion in immunology · 2026Review
- Donor-Related Factors Affecting Haploidentical HSCT Outcomes in Acute Leukemia: A Single-Center Retrospective Cohort Study of a Modified Combination of Anti-Thymocyte Globulin and Post-Transplant Cyclophosphamide.Health science reports · 2026Article
- Defying age: myth or reality?Haematologica · 2026Article
- Article
- Optimizing Haploidentical Donor Selection for Pediatric Hematopoietic Cell Transplant.Journal of clinical oncology : official journal of the American Society of Clinical Oncology · 2026Article
- Development and explainable AI-driven characterization of a prognostic model for haploidentical transplantation outcomes.NPJ digital medicine · 2026Article
- Donor leukocyte telomere length emerges as a prognostic factor for transplantation outcomes.Innovation (Cambridge (Mass.)) · 2026Article
- Challenging a clinical dogma with multimodal machine learning: a retrospective analysis of transplant mismatched donor selection.Leukemia · 2026Article
- Article
- When the first graft fails: a strategic approach to donor selection for second transplant.Haematologica · 2026Article
- Impact of donor selection in adverse-risk AML undergoing hematopoietic cell transplantation: A study from the EBMT Acute Leukemia Working Party.Bone marrow transplantation · 2026Article
- Matched unrelated vs haploidentical donor hematopoietic cell transplantation using posttransplant cyclophosphamide.Blood advances · 2026Article
- Future directions in transplantation for aplastic anemia.Hematology. American Society of Hematology. Education Program · 2025Review
- New age GVHD prophylaxis regimens: what works for what donor and why.Hematology. American Society of Hematology. Education Program · 2025Review
- Article
- Allogeneic Hematopoietic Cell Donor Selection: Contemporary Guidelines from the NMDP/CIBMTR.Transplantation and cellular therapy · 2025Review
12 more citing papers are in PubMed but not listed here.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
7 authors at 1 institution in 1 country.
Funding
Abstract
Allogeneic blood or marrow transplantation (BMT) physicians seek to optimize all possible variables to improve outcomes. Selectable factors include conditioning, graft-versus-host disease (GVHD) prophylaxis, graft source, and donor. Many patients, especially those with eligible haploidentical (haplo) donors, will have multiple donor options. We seek to identify factors to optimize the choice of haplo donors when using posttransplantation cyclophosphamide (PTCy) GVHD prophylaxis. We evaluated the effect of modifiable donor characteristics (donor age and relationship) on outcomes following haplo BMT with a uniform nonmyeloablative conditioning and PTCy. From 2002 to 2017, 889 consecutive adult patients underwent nonmyeloablative haplo BMT with PTCy. Median follow-up among survivors was 2.5 years after BMT. Median recipient age was 59 (range: 18 to 76) years and median donor age was 40 (range: 13 to 79) years. Multivariable analyses demonstrated that increasing donor age by decade was associated with poorer overall survival (hazard ratio [HR], 1.13 [1.05, 1.22; P = .0015]), worse progression-free survival (HR, 1.09 [1.02, 1.16; P = .015]), and a higher risk for grade 2 to 4 and grade 3 to 4 GVHD (1.3 [1.06, 1.61; P = .013]), but not for chronic GVHD (HR, 1.06 [0.94, 1.2]; P = .37). These less-favorable results with older donors were attributable to worse nonrelapse mortality (HR, 1.19 [1.05, 1.34]; P = .006), not relapse. Parents were associated with inferior outcomes compared with sibling donors, whereas no significant differences were observed between parental donors. These data suggest that the youngest, adult-sized donors should be preferred when multiple haplo donors are available.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.